Scholarly Index
Caroline R. Baumal
Apellis Pharmaceuticals (United States); 11,261 total citations; 290 total publications; best world rank #105
Apellis Pharmaceuticals (United States)
11,261Total citations
290Total publications
52H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Retinal Diseases and Treatments | Lifetime | 233 | US 119 | 99.10 |
| Retinal Imaging and Analysis | Lifetime | 177 | US 82 | 98.90 |
| Retinal and Optic Conditions | Lifetime | 151 | US 75 | 98.93 |
| Ocular Diseases and Behçet’s Syndrome | Lifetime | 170 | US 83 | 98.37 |
| Glaucoma and retinal disorders | Lifetime | 587 | US 253 | 98.48 |
| Retinal and Macular Surgery | Lifetime | 218 | US 103 | 97.97 |
| Intraocular Surgery and Lenses | Lifetime | 951 | US 384 | 96.05 |
| Retinopathy of Prematurity Studies | Lifetime | 407 | US 187 | 91.79 |
| Drug-Induced Ocular Toxicity | Lifetime | 842 | US 344 | 66.94 |
| Retinal Diseases and Treatments | 2021-2025 | 144 | US 42 | 98.23 |
| Ocular Diseases and Behçet’s Syndrome | 2021-2025 | 105 | US 28 | 95.46 |
| Retinal Imaging and Analysis | 2021-2025 | 276 | US 74 | 95.56 |
| Retinal and Optic Conditions | 2021-2025 | 203 | US 53 | 95.46 |
| Glaucoma and retinal disorders | 2021-2025 | 548 | US 143 | 94.20 |
| Retinopathy of Prematurity Studies | 2021-2025 | 806 | US 226 | 52.17 |